Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Looks To Build Around Xiidra, Sanofi Faces Toujeo Challenge, Amgen Downplays Romosozumab Data

Executive Summary

Shire, Sanofi and Amgen were among the companies presenting at the Bank of America Merrill Lynch Global Healthcare Conference Sept. 14-16 in London. Here are some key takeaways from those presentations.

You may also be interested in...

Sanofi/Regeneron's Great ODYSSEY ESCAPE – How Big Is Praluent's Apheresis Benefit?

The full data for Sanofi/Regeneron's ODYSSEY ESCAPE study of their PCSK9 inhibitor Praluent confirm its use in reducing the need for expensive apheresis procedures in severe hypercholesterolemia patients, but the extent of the cost savings is still unclear.

Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss

Losing Medivation could end up being a winning proposition for the French pharma if it can boost its cancer franchise another way, like by acquiring its partner in multiple collaborations Regeneron or making a less expensive takeout, such as Incyte or Ariad.

Will Radius Health's Abaloparatide Data Do The Trick In Osteoporosis?

Abaloparatide looks better for improving bone mass with less hypercalcemia than Lilly's first-in-class Forteo in the Phase III ACTIVE study, but it remains to be seen whether this will be enough to get ahead in the increasingly crowded osteoporosis market.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts